Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Chemists One Step Closer to Opioid Alternative

By Kenny Walter | May 22, 2019

With the opioid epidemic seemingly getting worse, researchers are working toward an addiction-free pain relief alternative.

A research team from the University of Virginia has discovered an enzyme called diacylglycerol lipase-beta (DAGLβ) that “chews up” fat molecules to produces chemical signals that control inflammation.

After identifying the enzyme as a possible drug target to reduce pain, the researchers found that selective molecules inhibit DAGLβ and reduce inflammation, similar to how aspirin and other non-steroidal anti-inflammatory drugs (NSAIDS) work.

However, in preclinical models, DAGLβ inhibitors provided pain relief without gastrointestinal toxicity when used over a long period of time, unlike NSAIDS. The researchers also found that DAGLβ inhibitors do not exhibit the addictive properties that opioids do.

“This could be a new route to treating long-term inflammation and pain without the side effects of toxicity and risk of addiction observed with current treatment options,” Ken Hsu, a chemistry professor at the University of Virginia, said in a statement. “Generally, if we block inflammation, we also affect the immune response. But we’re suggesting a different approach, one where we can stop inflammation without impacting the normal immune response.”

The researchers found in previous studies that were conducted in collaboration with researchers from Virginia Commonwealth University that DAGLβ inhibitors are highly effective at reducing different pain states, such as neuropathic pain and chemotherapy-induced peripheral neuropathy.

In the new study, the researchers discovered a new role for the enzyme in dendritic cells, a specialized type of innate immune cell that controls inflammation and activates the body’s infection fighting ability by stimulating T cells to produce an immune response.

Vaccination shows that the enzyme disruption does not affect dendritic cells immunogenic function in vivo while regulating lipopolysaccharide-stimulated tumor necrosis factor alpha response of primary dendritic cells. The enzyme also uncouples cytokine response and the CD8 + T cell priming capacity of dendritic cells.

“We found that by blocking DAGLβ, we can stop inflammation without affecting immunity,” Hsu said. “This supports the idea that DAGLβ is a viable target for long-term blockade of inflammation and pain without potentially compromising our immune system.”

According to the National Institute on Drug Abuse, 1.7 million people in the U.S. suffer from substance abuse disorders related to opioid use for pain relief, resulting in a $78 billion annual economic burden in health care and addiction treatment costs, lost worker productivity and increased criminal activity. More than 47,000 people in 2017 died due to drug abuse involving opioids or related drugs.

The study was published in Cell Chemical Biology.


Filed Under: Drug Discovery and Development

 

Related Articles Read More >

Collage of close-up male and female eyes isolated on colored neon backgorund. Multicolored stripes. Concept of equality, unification of all nations, ages and interests. Diversity and human rights
How a ‘rising tide’ of inclusivity is transforming clinical trials
Mary Marcus appointed CEO of NewAge Industries
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
Data analytics tools help doctors analyze trends in patient outcomes and population health.
External comparator studies: What researchers need to know to minimize bias
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE